CureVac reported on June 30 that its COVID-19 vaccine was 48 percent effective in the final analysis of its pivotal mass trial, only marginally better than the 47 percent shown after an initial read-out two weeks ago.
The German biotech firm stated that efficacy, measured by preventing symptomatic disease, was slightly better, at 53 percent, when excluding trial participants over 60 years old, the age group most affected by COVID-19.
